Key Highlights

  • Revenue and other income rose 30.63% to $4,839,901, and the loss after tax was $10,610,137, against $10,702,271 in FY25.
  • Net cash used in Operating Activities was $10,003,236, up 9.11% from $9,167,610, and cash at year end was $3,057,334.
  • The company says it is progressing towards sustainable Cash Flow breakeven but has not reached it.

Vitasora Health Limited (ASX:VHL) released its Appendix 4E preliminary final report for the year ended 30 June 2026. The financial statements on which the report is based have been audited.

Results

Revenue and other income rose 30.63% to $4,839,901. The loss after income tax attributable to members was $10,610,137 compared with $10,702,271 in FY25, a reduction of 0.86%. The loss per share was 0.58 cents against 0.77 cents, reflecting a larger share count. The company says that while it continued to invest in platform development, patient growth and operational capability, the result reflects increasing revenues and a focus on operational efficiency.

Cash flow

Net operating cash outflows were $10,003,236, compared with $9,167,610 in FY25, an increase of 9.11%. The company says outflows reduced during the second half of the year as management maintained expenditure controls and realised efficiencies from the platform transition. At year end the company held $3,057,334 in cash and cash equivalents and $2,656,241 in inventories. The operating outflow for the year is more than three times the year-end cash balance.

Net tangible assets and share count

Net tangible assets were $4,933,013 at 30 June 2026, compared with $1,656,855 a year earlier. The number of shares rose to 2,339,627,201 from 1,577,027,197, an increase of about 48%. Net tangible assets per share were 0.05 cents against 0.11 cents. The increase in share count reflects Capital raised during the year.

Platform and outlook

The company says its vCare platform is substantially implemented, Revenue conversion metrics are improving, patient enrolments are growing and its capital position is strengthened. It enters FY27 focused on increasing patient program volumes, improving Operating Leverage and progressing towards sustainable cash flow breakeven. These are stated aims, and the Appendix 4E does not set a date by which breakeven is expected to be reached.

Dividends

No dividends were paid during the year, and directors do not recommend a dividend. The report directs readers to the accompanying financial report for the detailed income statement, Balance Sheet and notes, which were not part of the summary provided here.

Putting the numbers side by side

The year's loss of $10.6 million was about 2.2 times revenue and other income of $4.8 million. The share count rose by about 48% to 2.34 billion, which is why the loss per share fell to 0.58 cents from 0.77 cents even though the total loss was almost unchanged. Net tangible assets rose to $4.9 million, but net tangible assets per share fell to 0.05 cents from 0.11 cents because of the larger share count.

Operational statements

The company links the second-half reduction in operating outflows to the platform transition and says patient enrolments are growing and revenue conversion is improving. It does not give enrolment numbers, per-patient revenue or a breakeven date in the Appendix 4E.